Why the study?
Heart failure with preserved ejection fraction is increasingly prevalent and morbid, and advances in imaging cardiac function and metabolism can provide an integrated assessment and identify measurable targets for novel medical therapy.
Advanced functional and metabolic imaging techniques offer promising utility for characterizing HFpEF and measuring outcomes for novel targeted therapies.
May guide HFpEF trial endpoints; leaves open clinical adoption pending prospective validation.
Heart failure with preserved ejection fraction (HFpEF) is recognised as an increasingly prevalent, morbid and burdensome condition with a poor outlook. Recent advances in both the understanding of HFpEF and the technological ability to image cardiac function and metabolism in humans have simultaneously shone a light on the molecular basis of this complex condition of diastolic dysfunction, and the inflammatory and metabolic changes that are associated with it, typically in the context of a complex patient. This review both makes the case for an integrated assessment of the condition, and highlights that metabolic alteration may be a measurable outcome for novel targeted forms of medical therapy. It furthermore highlights how recent technological advancements and advanced medical imaging techniques have enabled the characterisation of the metabolism and function of HFpEF within patients, at rest and during exercise.
No takes yet. Share an insight, caveat, or question.
Burrage et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: